AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02153918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PROSTVAC-F/TRICOM
Description: A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
Study NCT05646914 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex training exercises
Description: Squats and drop jumps, Barbell step-ups and hops, Bench press and plyometric press-up, Barbell lunge and box jumps were performed.
Study NCT05646914 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plyometric training exercises
Description: Drop Jumps, Hops, Plyometric press-up, Box Jumps were performed.
Study NCT03747471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetic Conversation Map
Description: Diabetic Conversation Map education tools are a series of tools for facilitated group education 5-8that were developed by Healthy Interactions in collaboration with the International Diabetes Federation (IDF) and are sponsored by Lilly Diabetes.~CM-based education guides people with diabetes through a process with the aim of helping them understand and internalize information about their disease and generate insightful conclusions, which may then result in improved self-management decisions and actions.
Study NCT00914069 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RIVS vascular access
Description: Access to peripheral vasculature
Study NCT00914069 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional vascular access
Description: Vascular access using conventional venous access device
Study NCT02029417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given SC
Study NCT02029417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omacetaxine mepesuccinate
Description: Given SC
Study NCT02029417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV
Study NCT02029417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00639509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cixutumumab
Description: Given IV
Study NCT00639509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo contrast-enhanced computed tomography
Study NCT00639509 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: contrast-enhanced magnetic resonance imaging
Description: Undergo contrast-enhanced magnetic resonance imaging
Study NCT05442658 — intervention group
Intervention type: OTHER
Intervention: Microbiota
Study NCT04529694 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Study NCT04113135 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: Participants will be lead through a series of yoga poses by a licensed physical therapist with advanced training in yoga. Participants in this group will also receive education related to MS as well as SMART goal setting, journaling and guided meditation. Modifications will be offered as needed.
Study NCT04113135 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Participants in this group will receive education related to MS as well as SMART goal setting, journaling, and guided meditation.
Study NCT03580018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid Powder
Description: Ten mL of Tranexamic Acid(100 mg/mL) was injected into the joint at the end of the operation.
Study NCT03580018 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Post-anterior cruciate ligament reconstruction (ACLR)
Description: Post-anterior cruciate ligament reconstruction (ACLR)
Study NCT03168945 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GeneXpert MTB/RIF
Description: Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
Study NCT03168945 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Smear microscopy
Description: Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
Study NCT02406820 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive hemodynamic monitoring (CVInsight™ [CVI])
Study NCT03424135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride soft capsules
Description: Single oral administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 capsules)
Study NCT03424135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium and diphenhydramine hydrochloride coated tablets (Aleve PM, BAY98-7111)
Description: Single administration of Naproxen sodium 220 mg/DPH HCl 25mg (2 tablets)
Study NCT03578042 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan and amlodipine and hydrochlorothiazide
Description: this is a fixed combination containing the 3 drugs
Study NCT00922753 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AI-6/PEEP-4
Description: Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
Study NCT03223662 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chemoradiotherapy
Description: Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m(2))x5 for two cycles. Radiation: a total dose of 40.4 Gray (Gy) will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
Study NCT03578042 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Standard of care
Description: any free triple combination therapy for hypertension given as 2 or 3 pills
Study NCT03223662 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Esophagectomy
Description: Minimally-invasive esophagectomy (RAMIE) or traditional open approach if necessary.
Study NCT00728897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 new formulation
Description: GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
Study NCT01254370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: 0.005%
Study NCT01254370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Travatan Z
Description: 0.004%
Study NCT01703468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxcarbazepine
Study NCT04283318 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 12h fasting
Description: 12h fasting (overnight)
Study NCT04283318 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: 36h fasting
Description: 36h fasting ( one day and two nights fasting)
Study NCT00802971 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: FOS
Description: Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
Study NCT02726347 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PPV-23
Description: one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
Study NCT00570947 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPR Anytime Kit
Description: The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
Study NCT01350219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stem Cell Educator
Description: For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 \~ 9 hrs.
Study NCT02937597 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ePBP: eProficiency Based Progression
Description: National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
Study NCT02937597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: eS: eScenarios
Description: National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
Study NCT02937597 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HSE
Description: National HSE e-learning programme only
Study NCT01777841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Electronic Care plan delivery
Study NCT01777841 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard care
Study NCT01565577 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenbVac
Description: Blood test
Study NCT02444026 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCBT for Insomnia
Description: Internet-delivered Cognitive Behavioural Therapy for Insomnia
Study NCT02149134 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TeHF2013-01
Study NCT03012646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Treprostinil
Description: Inhaled treprostinil (6 mcg/breath) administered four times daily
Study NCT02333643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLS003
Study NCT02333643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Study NCT02333643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT02333643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle topical
Study NCT03678077 — intervention group
Intervention type: OTHER
Intervention: Mild traumatic brain injury
Description: This is a register based observational study and does not include interventions. Exposure is mild traumatic brain injury.
Study NCT06522113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: patients were given cilostazol 100mg twice a day with aspirin
Study NCT06522113 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: patients were given clopidogrel 75mg with aspirin
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil 50 mg
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil 100 mg
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Udenafil 150 mg
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching 50 mg Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching 50 mg Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching 100 mg Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching 100 mg Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Matching 150 mg Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT01065012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matching 150 mg Udenafil
Description: Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
Study NCT00761878 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to plasma energy
Description: Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
Study NCT03886272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 (Test)
Description: tablet
Study NCT03886272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 (Reference)
Description: tablet
Study NCT00325416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: (Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)
Study NCT00325416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: (Days -4,-3,-2) 50 mg/m\^2/day IV over 30 minutes (total dose 150 mg/m\^2)
Study NCT00325416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan (TPT)
Description: Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)
Study NCT00325416 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: topotecan (TPT)
Description: Phase I Dose Escalation: Level 1 - 20 mg/m\^2; Level 2 - 30 mg/m\^2; Level 4 - 54 mg/m\^2; Level 5 - 72 mg/m\^2; Level 6 - 96 mg/m\^2; Level 7 - 127.8 mg/m\^2; Level 8 - 170.1 mg/m\^2~Phase II: Treatment at maximum tolerated dose (MTD)
Study NCT00325416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Stem Cell Rescue
Description: Day 0
Study NCT00325416 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Rescue
Description: Day 0
Study NCT01299909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Training for Smokers
Description: 8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
Study NCT01299909 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Training for Smokers
Description: 8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
Study NCT01299909 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quitline
Description: Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
Study NCT05217030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animal assisted therapy
Description: Patients in AAT group had handler place dog on bed and patient's hand was placed on dog. Bedside RN measured GCS, RLAS, LoCmds before and after intervention
Study NCT02524938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorogenic Acid (CGA) enriched coffee
Description: Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.~Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)
Study NCT02524938 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Conventional coffee
Description: Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
Study NCT01737801 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung function test
Description: Lung function test.
Study NCT00728897 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK598809 old formulation
Description: GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
Study NCT02868515 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hot cereal contain 3 g dietary fiber
Description: Intervention involves consumption of a hot cereal over 14 day period
Study NCT03238131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
Study NCT03238131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
Study NCT03238131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
Study NCT02601300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Study NCT02072785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine Sulfate Liposome
Study NCT02072785 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine Sulfate
Study NCT01258842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis HN019
Description: B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
Study NCT01258842 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo sachet, consumed once per day for 12 weeks
Study NCT01691170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching Hamstring
Study NCT01691170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quadriceps Strengthening
Study NCT02611336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: Tadalafil 20 mg to be taken orally once daily, for 3 months
Study NCT02791178 — intervention group
Intervention type: PROCEDURE
Intervention: Optical coherence tomography (OCT)
Description: Special camera to study part of your heart that was affected
Study NCT02791178 — intervention group
Intervention type: PROCEDURE
Intervention: Index of microcirculatory resistance (IMR)
Description: Special wire to study part of your heart that was affected
Study NCT02791178 — intervention group
Intervention type: OTHER
Intervention: Cardiac MRI
Description: Special scanner if the heart to assess the damage of your heart
Study NCT03122223 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ALVAC-HIV (vCP2438)
Description: expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer greater than or equal to 1 × 10\^6 cell culture infectious dose (CCID)50 and less than 1 × 10\^8 CCID50 (nominal dose of 10\^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
Study NCT03238131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
Study NCT02493959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY1-36 infusion
Description: Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
Study NCT02493959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY1-36 + sitagliptin
Description: Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
Study NCT02493959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PYY3-36 infusion
Description: 0.8 pmol/kg/min infusion of PYY3-36.
Study NCT03122223 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bivalent subtype C gp120/MF59
Description: clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
Study NCT02493959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: placebo
Description: Infusion of saline for 2 hrs.
Study NCT01414244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Drug